The VALOR Study for Dermatomyositis with MSU

Priovant Therapeutics joins Myositis Support and Understanding (MSU) again for a fireside chat-type discussion about the VALOR Study. The study aims to learn more about the effectiveness and safety of the investigational medication brepocitinib in adults living with dermatomyositis. Investigational medicine means that it has not been approved by country-specific regulatory health authorities to be used for dermatomyositis and its use is being allowed for research purposes only. Brepocitinib will be compared to a placebo (placebo looks like brepocitinib but contains no active medicine). Participants in the study will take 3 tablets by mouth every day.
Participants in the study must have both muscle and skin problems caused by dermatomyositis. Brepocitinib is designed to block the part of the immune system involved in causing the inflammation seen in dermatomyositis.
Eligible participants for the trial must:
Be 18 to 74 years old
Have a diagnosis of dermatomyositis previously confirmed by a healthcare provider
There are additional eligibility requirements, which the study doctor will explain. To learn more about study participation, and to see if you or someone you know may qualify, visit the VALOR study website at valorstudy.com/

[@user-ye9be6rb7f]

Can you please share some insights on the challenges faced for the recruitment in Dermatomyositis trials; Anything specific Priovant Therapeutics faced during recruitment and what was done to overcome the same